Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina
Zika virus (ZIKV) is a mosquito-borne flavivirus that causes an acute febrile illness. ZIKV can be transmitted between sexual partners and from mother to fetus. Infection is strongly associated with neurologic complications in adults, including Guillain-Barré syndrome and myelitis, and congenital ZI...
Saved in:
Published in | Frontiers in virology (online) Vol. 3 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
01.01.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Zika virus (ZIKV) is a mosquito-borne flavivirus that causes an acute febrile illness. ZIKV can be transmitted between sexual partners and from mother to fetus. Infection is strongly associated with neurologic complications in adults, including Guillain-Barré syndrome and myelitis, and congenital ZIKV infection can result in fetal injury and congenital Zika syndrome (CZS). Development of an effective vaccine is imperative to protect against ZIKV vertical transmission and CZS. Recombinant Vesicular Stomatitis virus (rVSV) is a highly effective and safe vector for the delivery of foreign immunogens for vaccine purposes. Here, we evaluate an rVSV vaccine expressing the full length pre-membrane (prM) and ZIKV envelope (E) proteins (VSV-ZprME), shown to be immunogenic in murine models of ZIKV infection, for its capacity to induce immune responses in nonhuman primates. Moreover, we assess the efficacy of the rVSVΔM-ZprME vaccine in the protection of pigtail macaques against ZIKV infection. Administration of the rVSVΔM-ZprME vaccine was safe, but it did not induce robust anti-ZIKV T-cell responses, IgM or IgG antibodies, or neutralizing antibodies in most animals. Post ZIKV challenge, animals that received the rVSVΔM control vaccine lacking ZIKV antigen had higher levels of plasma viremia compared to animals that received the rVSVΔM-ZprME vaccine. Anti-ZIKV neutralizing Ab titers were detected in a single animal that received the rVSVΔM-ZprME vaccine that was associated with reduced plasma viremia. The overall suboptimal ZIKV-specific cellular and humoral responses post-immunization indicates the rVSVΔM-ZprME vaccine did not elicit an immune response in this pilot study. However, recall antibody response to the rVSVΔM-ZprME vaccine indicates it may be immunogenic and further developments to the vaccine construct could enhance its potential as a vaccine candidate in a nonhuman primate pre-clinical model. |
---|---|
AbstractList | Zika virus (ZIKV) is a mosquito-borne flavivirus that causes an acute febrile illness. ZIKV can be transmitted between sexual partners and from mother to fetus. Infection is strongly associated with neurologic complications in adults, including Guillain-Barré syndrome and myelitis, and congenital ZIKV infection can result in fetal injury and congenital Zika syndrome (CZS). Development of an effective vaccine is imperative to protect against ZIKV vertical transmission and CZS. Recombinant Vesicular Stomatitis virus (rVSV) is a highly effective and safe vector for the delivery of foreign immunogens for vaccine purposes. Here, we evaluate an rVSV vaccine expressing the full length pre-membrane (prM) and ZIKV envelope (E) proteins (VSV-ZprME), shown to be immunogenic in murine models of ZIKV infection, for its capacity to induce immune responses in nonhuman primates. Moreover, we assess the efficacy of the rVSVΔM-ZprME vaccine in the protection of pigtail macaques against ZIKV infection. Administration of the rVSVΔM-ZprME vaccine was safe, but it did not induce robust anti-ZIKV T-cell responses, IgM or IgG antibodies, or neutralizing antibodies in most animals. Post ZIKV challenge, animals that received the rVSVΔM control vaccine lacking ZIKV antigen had higher levels of plasma viremia compared to animals that received the rVSVΔM-ZprME vaccine. Anti-ZIKV neutralizing Ab titers were detected in a single animal that received the rVSVΔM-ZprME vaccine that was associated with reduced plasma viremia. The overall suboptimal ZIKV-specific cellular and humoral responses post-immunization indicates the rVSVΔM-ZprME vaccine did not elicit an immune response in this pilot study. However, recall antibody response to the rVSVΔM-ZprME vaccine indicates it may be immunogenic and further developments to the vaccine construct could enhance its potential as a vaccine candidate in a nonhuman primate pre-clinical model. Zika virus (ZIKV) is a mosquito-borne flavivirus that causes an acute febrile illness. ZIKV can be transmitted between sexual partners and from mother to fetus. Infection is strongly associated with neurologic complications in adults, including Guillain-Barré syndrome and myelitis, and congenital ZIKV infection can result in fetal injury and congenital Zika syndrome (CZS). Development of an effective vaccine is imperative to protect against ZIKV vertical transmission and CZS. Recombinant Vesicular Stomatitis virus (rVSV) is a highly effective and safe vector for the delivery of foreign immunogens for vaccine purposes. Here, we evaluate an rVSV vaccine expressing the full length pre-membrane (prM) and ZIKV envelope (E) proteins (rVSVΔM-ZprME), shown to be immunogenic in murine models of ZIKV infection, for its capacity to induce immune responses in nonhuman primates. Moreover, we assess the efficacy of the rVSVΔM-ZprME vaccine in the protection of pigtail macaques against ZIKV infection. Administration of the rVSVΔM-ZprME vaccine was safe, but it did not induce robust anti-ZIKV T-cell responses, IgM or IgG antibodies, or neutralizing antibodies in most animals. Post ZIKV challenge, animals that received the rVSVΔM control vaccine lacking ZIKV antigen had higher levels of plasma viremia compared to animals that received the rVSVΔM-ZprME vaccine. Anti-ZIKV neutralizing Ab titers were detected in a single animal that received the rVSVΔM-ZprME vaccine that was associated with reduced plasma viremia. The overall suboptimal ZIKV-specific cellular and humoral responses post-immunization indicates the rVSVΔM-ZprME vaccine did not elicit an immune response in this pilot study. However, recall antibody response to the rVSVΔM-ZprME vaccine indicates it may be immunogenic and further developments to the vaccine construct could enhance its potential as a vaccine candidate in a nonhuman primate pre-clinical model. |
Author | Grant, Richard F Edlefsen, Paul T Muruato, Antonio E Iwayama, Naoto Voss, Kathleen M Finn, Eric E Fuller, Deborah H Kuller, LaRene Gale, Jr, Michael Betancourt, Dillon Murnane, Robert D O'Connor, Megan A Lewis, Thomas B Wangari, Solomon Ahrens, Joel Tisoncik-Go, Jennifer Barber, Glen N |
AuthorAffiliation | 3 Washington National Primate Research Center, Seattle, WA 7 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 1 Department of Immunology, School of Medicine, University of Washington, Seattle, WA 2 Center for innate immunity and immune disease, University of Washington, Seattle, WA 6 Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL 4 Department of Microbiology, School of Medicine, University of Washington, Seattle, WA 5 Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA |
AuthorAffiliation_xml | – name: 2 Center for innate immunity and immune disease, University of Washington, Seattle, WA – name: 3 Washington National Primate Research Center, Seattle, WA – name: 4 Department of Microbiology, School of Medicine, University of Washington, Seattle, WA – name: 5 Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA – name: 7 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA – name: 6 Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL – name: 1 Department of Immunology, School of Medicine, University of Washington, Seattle, WA |
Author_xml | – sequence: 1 givenname: Jennifer surname: Tisoncik-Go fullname: Tisoncik-Go, Jennifer organization: Washington National Primate Research Center, Seattle, WA – sequence: 2 givenname: Kathleen M surname: Voss fullname: Voss, Kathleen M organization: Washington National Primate Research Center, Seattle, WA – sequence: 3 givenname: Thomas B surname: Lewis fullname: Lewis, Thomas B organization: Department of Microbiology, School of Medicine, University of Washington, Seattle, WA – sequence: 4 givenname: Antonio E surname: Muruato fullname: Muruato, Antonio E organization: Department of Immunology, School of Medicine, University of Washington, Seattle, WA – sequence: 5 givenname: LaRene surname: Kuller fullname: Kuller, LaRene organization: Washington National Primate Research Center, Seattle, WA – sequence: 6 givenname: Eric E surname: Finn fullname: Finn, Eric E organization: Washington National Primate Research Center, Seattle, WA – sequence: 7 givenname: Dillon surname: Betancourt fullname: Betancourt, Dillon organization: Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL – sequence: 8 givenname: Solomon surname: Wangari fullname: Wangari, Solomon organization: Washington National Primate Research Center, Seattle, WA – sequence: 9 givenname: Joel surname: Ahrens fullname: Ahrens, Joel organization: Washington National Primate Research Center, Seattle, WA – sequence: 10 givenname: Naoto surname: Iwayama fullname: Iwayama, Naoto organization: Washington National Primate Research Center, Seattle, WA – sequence: 11 givenname: Richard F surname: Grant fullname: Grant, Richard F organization: Washington National Primate Research Center, Seattle, WA – sequence: 12 givenname: Robert D surname: Murnane fullname: Murnane, Robert D organization: Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA – sequence: 13 givenname: Paul T surname: Edlefsen fullname: Edlefsen, Paul T organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 14 givenname: Deborah H surname: Fuller fullname: Fuller, Deborah H organization: Department of Microbiology, School of Medicine, University of Washington, Seattle, WA – sequence: 15 givenname: Glen N surname: Barber fullname: Barber, Glen N organization: Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL – sequence: 16 givenname: Michael surname: Gale, Jr fullname: Gale, Jr, Michael organization: Washington National Primate Research Center, Seattle, WA – sequence: 17 givenname: Megan A surname: O'Connor fullname: O'Connor, Megan A organization: Department of Microbiology, School of Medicine, University of Washington, Seattle, WA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37383986$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkUtvFDEQhC0URELIH-CAfOSyi58z9gmhKECkSByACHGxej3tjcOMHeyZlfbfM_sgSk623FVfl1yvyUnKCQl5y9lSSmM_hE0seSmYkEvOmVGCvSBnomnlwnDz6-TJ_ZRc1HrPGBPtTmZfkVPZSiOtac5IudpAP8EYc6I50PEOaRyGKeU1pujjuKWQOoohRA9-u5NAouX2-y3dgPcxIYU1xFRH-jv-ATqHmiqNKaDfI2OiA8xOoAkHrGOJCd6QlwH6ihfH85z8_Hz14_Lr4ubbl-vLTzcLL60dF950WuvZGlYclBUapW-ZMhIkWACuW9-CCaCRiwYUKmVNZ7lvrG1Rey7PyfWB22W4dw8lDlC2LkN0-4dc1g7KGH2PTrZcoJ8XhaCUttI2HYcVk1Y0WnqmZtbHA-thWg3YeUxjgf4Z9PkkxTu3zhvHmWSNULs074-Ekv9O81e4IVaPfQ8J81SdMJIL2zKrZ6k4SH3JtRYMj3s4c7vy3b58tyvfHcufTe-eJny0_K9a_gN-xK-Y |
CitedBy_id | crossref_primary_10_1128_spectrum_03651_23 crossref_primary_10_3390_pathogens12081035 |
Cites_doi | 10.1503/cmaj.170074 10.1016/j.celrep.2019.02.062 10.1056/NEJMoa1502924 10.1016/j.vaccine.2008.11.087 10.1038/s41467-018-05826-w 10.3389/fimmu.2021.774026 10.1128/JVI.00640-19 10.1001/jamapediatrics.2016.3982 10.1016/S0140-6736(17)33106-9 10.1126/science.aai9137 10.1101/2021.01.19.426885 10.1056/NEJMoa1414216 10.1126/science.aaf8505 10.1080/713803696 10.1128/jvi.01337-22 10.1016/j.jaut.2016.12.007 10.1038/nature21428 10.1016/j.omto.2018.12.001 10.1016/j.vaccine.2016.06.071 10.1016/j.chom.2016.04.013 10.15585/mmwr.mm7108a2 10.1038/nm.4193 10.1128/MCB.20.22.8590-8601.2000 10.1016/S0140-6736(16)32621-6 10.1038/s41541-019-0155-z 10.1016/S0140-6736(17)33105-7 10.1038/nm.4485 10.1016/j.jviromet.2019.05.011 10.1016/S0140-6736(16)30058-7 10.1016/j.cell.2017.04.024 10.1093/infdis/jix336 10.1038/s41598-018-29401-x 10.1016/j.ebiom.2019.09.055 10.1128/JVI.01469-17 10.1128/JVI.76.2.895-904.2002 10.1371/journal.pntd.0005869 10.1007/s00705-006-0903-z 10.4269/ajtmh.2001.65.405 10.1128/mBio.00597-19 10.1073/pnas.1209591110 10.3201/eid2508.190281 10.4049/jimmunol.1602180 10.3390/vaccines10030435 |
ContentType | Journal Article |
DBID | NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.3389/fviro.2023.1108420 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2673-818X |
ExternalDocumentID | oai_doaj_org_article_3712ecfb1ff4459396d1ab0392653c04 10_3389_fviro_2023_1108420 37383986 |
Genre | Journal Article |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R01 AI145296 – fundername: NIH HHS grantid: U42 OD011123 – fundername: NIMH NIH HHS grantid: K01 MH123258 – fundername: NIH HHS grantid: P51 OD010425 – fundername: NIAID NIH HHS grantid: R01 AI143265 |
GroupedDBID | 9T4 AAFWJ AFPKN ALMA_UNASSIGNED_HOLDINGS ARCSS GROUPED_DOAJ M~E NPM OK1 AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c399t-c8d555acafb1a4925e3c70483a3a9aa157c7a8fa5e126a4e4498d91c6997e5c13 |
IEDL.DBID | DOA |
ISSN | 2673-818X |
IngestDate | Thu Jul 04 21:10:19 EDT 2024 Tue Sep 17 21:30:12 EDT 2024 Fri Jun 28 19:58:43 EDT 2024 Fri Aug 23 00:55:47 EDT 2024 Fri Oct 18 08:42:11 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c399t-c8d555acafb1a4925e3c70483a3a9aa157c7a8fa5e126a4e4498d91c6997e5c13 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 J.T.-G. and M.A.O. wrote the manuscript, led the study, generated data and performed data analysis. K.V., T.B.L., A.E.M, L.K., E.E.F., and R.F.G. generated data and performed data analysis. D.B. and G.N.B. provided the vaccine constructs. S.W., J.A. and N.I. performed the experimental procedures, collected specimens, and provided care for the animals. R.D.M. performed necropsy, specimen collection, and gross and microscopic evaluation of tissues and organs. P.T.E. provided statistical guidance. G.N.B., D.H.F., and M.G. Jr. conceptualized the study and edited the manuscript. Author Contributions |
OpenAccessLink | https://doaj.org/article/3712ecfb1ff4459396d1ab0392653c04 |
PMID | 37383986 |
PQID | 2831297095 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_3712ecfb1ff4459396d1ab0392653c04 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10306241 proquest_miscellaneous_2831297095 crossref_primary_10_3389_fviro_2023_1108420 pubmed_primary_37383986 |
PublicationCentury | 2000 |
PublicationDate | 20230101 |
PublicationDateYYYYMMDD | 2023-01-01 |
PublicationDate_xml | – month: 1 year: 2023 text: 20230101 day: 1 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in virology (online) |
PublicationTitleAlternate | Front Virol |
PublicationYear | 2023 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Ao (B23) 2022; 96 Brasil (B8) 2016; 387 Fernandez (B16) 2002; 76 Malenfant (B21) 2022; 71 O'Donnell (B26) 2022; 10 O'Connor (B30) 2018; 9 ElSherif (B36) 2017; 189 Melzer (B18) 2019; 12 Gaudinski (B11) 2018; 391 Moore (B9) 2017; 171 Pardi (B15) 2017; 543 Clarke (B35) 2016; 34 Grifoni (B3) 2017; 91 Furuyama (B25) 2022; 2022 Agnandji (B19) 2016; 374 Furuyama (B24) 2020; 5 Regules (B22) 2017; 376 Robbiani (B33) 2017; 169 Petersen (B28) 2000; 20 Menicucci (B40) 2019; 10 Henao-Restrepo (B20) 2017; 389 Iyer (B27) 2009; 27 Marzi (B42) 2019; 49 Durbin (B14) 2001; 65 Esser-Nobis (B34) 2019; 93 Dowd (B12) 2016; 354 Styczynski (B10) 2017; 11 Kuno (B1) 2007; 152 Marzi (B6) 2021; 12 Basile (B32) 2019; 271 Adams Waldorf (B43) 2016; 22 Anaya (B7) 2017; 77 Marzi (B39) 2013; 110 Emanuel (B41) 2018; 8 Adams Waldorf (B31) 2018; 24 Balachandran (B17) 2000; 50 Stettler (B4) 2016; 353 Modjarrad (B13) 2018; 391 Wang (B5) 2019; 26 Stein (B38) 2019; 25 Jusu (B37) 2018; 217 Dai (B2) 2016; 19 Betancourt (B29) 2017; 198 |
References_xml | – volume: 189 year: 2017 ident: B36 article-title: Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial publication-title: CMAJ doi: 10.1503/cmaj.170074 contributor: fullname: ElSherif – volume: 26 start-page: 3360 year: 2019 ident: B5 article-title: Structural basis for neutralization and protection by a zika virus-specific human antibody publication-title: Cell Rep doi: 10.1016/j.celrep.2019.02.062 contributor: fullname: Wang – volume: 374 year: 2016 ident: B19 article-title: Phase 1 trials of rVSV Ebola vaccine in Africa and Europe publication-title: N Engl J Med doi: 10.1056/NEJMoa1502924 contributor: fullname: Agnandji – volume: 27 start-page: 893 year: 2009 ident: B27 article-title: Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01 publication-title: Vaccine doi: 10.1016/j.vaccine.2008.11.087 contributor: fullname: Iyer – volume: 9 start-page: 3371 year: 2018 ident: B30 article-title: Early cellular innate immune responses drive zika viral persistence and tissue tropism in pigtail macaques publication-title: Nat Commun doi: 10.1038/s41467-018-05826-w contributor: fullname: O'Connor – volume: 12 year: 2021 ident: B6 article-title: Single dose of a VSV-based vaccine rapidly protects macaques from marburg virus disease publication-title: Front Immunol doi: 10.3389/fimmu.2021.774026 contributor: fullname: Marzi – volume: 93 year: 2019 ident: B34 article-title: Comparative analysis of African and Asian lineage-derived zika virus strains reveals differences in activation of and sensitivity to antiviral innate immunity publication-title: J Virol doi: 10.1128/JVI.00640-19 contributor: fullname: Esser-Nobis – volume: 171 year: 2017 ident: B9 article-title: Characterizing the pattern of anomalies in congenital zika syndrome for pediatric clinicians publication-title: JAMA pediatrics. doi: 10.1001/jamapediatrics.2016.3982 contributor: fullname: Moore – volume: 391 year: 2018 ident: B13 article-title: Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated zika virus vaccine candidate: Phase 1, randomised, double-blind, placebo-controlled clinical trials publication-title: Lancet doi: 10.1016/S0140-6736(17)33106-9 contributor: fullname: Modjarrad – volume: 354 year: 2016 ident: B12 article-title: Rapid development of a DNA vaccine for zika virus publication-title: Science doi: 10.1126/science.aai9137 contributor: fullname: Dowd – volume: 2022 year: 2022 ident: B25 article-title: Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a vesicular stomatitis virus-based vaccine publication-title: mBio doi: 10.1101/2021.01.19.426885 contributor: fullname: Furuyama – volume: 376 year: 2017 ident: B22 article-title: A recombinant vesicular stomatitis virus Ebola vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa1414216 contributor: fullname: Regules – volume: 353 year: 2016 ident: B4 article-title: Specificity, cross-reactivity, and function of antibodies elicited by zika virus infection publication-title: Science doi: 10.1126/science.aaf8505 contributor: fullname: Stettler – volume: 50 year: 2000 ident: B17 article-title: Vesicular stomatitis virus (VSV) therapy of tumors publication-title: IUBMB Life doi: 10.1080/713803696 contributor: fullname: Balachandran – volume: 96 year: 2022 ident: B23 article-title: A recombinant VSV-based bivalent vaccine effectively protects against both SARS-CoV-2 and influenza a virus infection publication-title: J Virol doi: 10.1128/jvi.01337-22 contributor: fullname: Ao – volume: 77 year: 2017 ident: B7 article-title: A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the zika virus outbreak in cucuta, Colombia publication-title: J Autoimmun doi: 10.1016/j.jaut.2016.12.007 contributor: fullname: Anaya – volume: 543 year: 2017 ident: B15 article-title: Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination publication-title: Nature doi: 10.1038/nature21428 contributor: fullname: Pardi – volume: 12 start-page: 26 year: 2019 ident: B18 article-title: Enhanced safety and efficacy of oncolytic VSV therapy by combination with T cell receptor transgenic T cells as carriers publication-title: Mol Ther Oncolytics. doi: 10.1016/j.omto.2018.12.001 contributor: fullname: Melzer – volume: 34 year: 2016 ident: B35 article-title: Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment publication-title: Vaccine doi: 10.1016/j.vaccine.2016.06.071 contributor: fullname: Clarke – volume: 19 start-page: 696 year: 2016 ident: B2 article-title: Structures of the zika virus envelope protein and its complex with a flavivirus broadly protective antibody publication-title: Cell Host Microbe doi: 10.1016/j.chom.2016.04.013 contributor: fullname: Dai – volume: 71 year: 2022 ident: B21 article-title: Use of Ebola vaccine: Expansion of recommendations of the advisory committee on immunization practices to include two additional populations - united states, 2021 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7108a2 contributor: fullname: Malenfant – volume: 22 year: 2016 ident: B43 article-title: Fetal brain lesions after subcutaneous inoculation of zika virus in a pregnant nonhuman primate publication-title: Nat Med doi: 10.1038/nm.4193 contributor: fullname: Adams Waldorf – volume: 20 year: 2000 ident: B28 article-title: The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes publication-title: Mol Cell Biol doi: 10.1128/MCB.20.22.8590-8601.2000 contributor: fullname: Petersen – volume: 389 year: 2017 ident: B20 article-title: Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca suffit!) publication-title: Lancet doi: 10.1016/S0140-6736(16)32621-6 contributor: fullname: Henao-Restrepo – volume: 5 start-page: 4 year: 2020 ident: B24 article-title: A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades publication-title: NPJ Vaccines doi: 10.1038/s41541-019-0155-z contributor: fullname: Furuyama – volume: 391 year: 2018 ident: B11 article-title: Safety, tolerability, and immunogenicity of two zika virus DNA vaccine candidates in healthy adults: Randomised, open-label, phase 1 clinical trials publication-title: Lancet doi: 10.1016/S0140-6736(17)33105-7 contributor: fullname: Gaudinski – volume: 24 year: 2018 ident: B31 article-title: Congenital zika virus infection as a silent pathology with loss of neurogenic output in the fetal brain publication-title: Nat Med doi: 10.1038/nm.4485 contributor: fullname: Adams Waldorf – volume: 271 start-page: 113671 year: 2019 ident: B32 article-title: Performance of InBios ZIKV detect 2.0 IgM capture ELISA in two reference laboratories compared to the original ZIKV detect IgM capture ELISA publication-title: J Virol Methods doi: 10.1016/j.jviromet.2019.05.011 contributor: fullname: Basile – volume: 387 start-page: 1482 year: 2016 ident: B8 article-title: Guillain-Barre syndrome associated with zika virus infection publication-title: Lancet doi: 10.1016/S0140-6736(16)30058-7 contributor: fullname: Brasil – volume: 169 start-page: 597 year: 2017 ident: B33 article-title: Recurrent potent human neutralizing antibodies to zika virus in Brazil and Mexico publication-title: Cell doi: 10.1016/j.cell.2017.04.024 contributor: fullname: Robbiani – volume: 217 year: 2018 ident: B37 article-title: Rapid establishment of a cold chain capacity of -60 degrees c or colder for the STRIVE Ebola vaccine trial during the Ebola outbreak in Sierra Leone publication-title: J Infect Dis doi: 10.1093/infdis/jix336 contributor: fullname: Jusu – volume: 8 start-page: 11043 year: 2018 ident: B41 article-title: A VSV-based zika virus vaccine protects mice from lethal challenge publication-title: Sci Rep doi: 10.1038/s41598-018-29401-x contributor: fullname: Emanuel – volume: 49 year: 2019 ident: B42 article-title: Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge publication-title: EBioMedicine doi: 10.1016/j.ebiom.2019.09.055 contributor: fullname: Marzi – volume: 91 year: 2017 ident: B3 article-title: Prior dengue virus exposure shapes T cell immunity to zika virus in humans publication-title: J Virol doi: 10.1128/JVI.01469-17 contributor: fullname: Grifoni – volume: 76 start-page: 895 year: 2002 ident: B16 article-title: Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease publication-title: J Virol doi: 10.1128/JVI.76.2.895-904.2002 contributor: fullname: Fernandez – volume: 11 year: 2017 ident: B10 article-title: Increased rates of Guillain-barre syndrome associated with zika virus outbreak in the Salvador metropolitan area, Brazil publication-title: PloS Negl Trop Dis doi: 10.1371/journal.pntd.0005869 contributor: fullname: Styczynski – volume: 152 year: 2007 ident: B1 article-title: Full-length sequencing and genomic characterization of bagaza, kedougou, and zika viruses publication-title: Arch Virol doi: 10.1007/s00705-006-0903-z contributor: fullname: Kuno – volume: 65 year: 2001 ident: B14 article-title: Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.2001.65.405 contributor: fullname: Durbin – volume: 10 year: 2019 ident: B40 article-title: Antiviral innate responses induced by VSV-EBOV vaccination contribute to rapid protection publication-title: mBio doi: 10.1128/mBio.00597-19 contributor: fullname: Menicucci – volume: 110 year: 2013 ident: B39 article-title: Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates publication-title: Proc Natl Acad Sci U S A. doi: 10.1073/pnas.1209591110 contributor: fullname: Marzi – volume: 25 year: 2019 ident: B38 article-title: Evaluating temperature sensitivity of vesicular stomatitis virus-based vaccines publication-title: Emerg Infect Dis doi: 10.3201/eid2508.190281 contributor: fullname: Stein – volume: 198 year: 2017 ident: B29 article-title: Cutting edge: Innate immune augmenting vesicular stomatitis virus expressing zika virus proteins confers protective immunity publication-title: J Immunol doi: 10.4049/jimmunol.1602180 contributor: fullname: Betancourt – volume: 10 year: 2022 ident: B26 article-title: VSV-based vaccines reduce virus shedding and viral load in hamsters infected with SARS-CoV-2 variants of concern publication-title: Vaccines (Basel). doi: 10.3390/vaccines10030435 contributor: fullname: O'Donnell |
SSID | ssj0002784209 |
Score | 2.274894 |
Snippet | Zika virus (ZIKV) is a mosquito-borne flavivirus that causes an acute febrile illness. ZIKV can be transmitted between sexual partners and from mother to... |
SourceID | doaj pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
SubjectTerms | immune response nonhuman primate rVSV vector vaccine Zika virus |
Title | Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37383986 https://search.proquest.com/docview/2831297095 https://pubmed.ncbi.nlm.nih.gov/PMC10306241 https://doaj.org/article/3712ecfb1ff4459396d1ab0392653c04 |
Volume | 3 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBUlUOil9CNtnTZBgdyKm9Xqyzo2YUMIpJc2IfQixpLcuiHasNkt5NLfnhnbu-yGQi-9GGPLWJ4ZoyfN6D3GDmoxbhDGppLIvUpV6VSCFLFU0JHvkQgcZXTPv5jTC3V2pa_WpL6oJqynB-4NdyitGKfQ1KJplNJOOhMF1CMc1o2WYWACFXptMvVrSKeNR67fJYOzMHfY0LaxTyQW3lW-KxL4XhuJOsL-v6HMx8WSa6PPyQv2fICN_HPf3ZfsScqv2NNeSPL-NZtNVqTdfNpwBHW8pY0fUwyPNiDQ5pAjT0QXAeGemkDms8uvl_w3BEqtc_gBLSJF_r29Bo4fsbjjyzqtjGf8BvBJ4DndJFL6yLDNLk4m345Py0FNoQwIQuZlqKLWGpuiLYEoCZMMlgjlQYIDENoGC1UDOomxAZWUclV0IhjnbNJByDdsK09zesc4UcqAbQRYqFW0pq60kjKZCHEkIqiCfVxa1t_2pBkeJxvkB9_5wZMf_OCHgh2R8VctifC6u4Bh4Icw8P8Kg4LtL13n8QehrAfkNF3cecRPiGksQsmCve1duXoV0TpJV5mCVRtO3ujL5p3c_uxIuEmezSD82fkfvX_PnpFF-qWdD2xrPlukXQQ783qvi2s8nv-ZPAAp3f5r |
link.rule.ids | 230,315,786,790,870,891,2115,27955,27956 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+the+immunogenicity+and+efficacy+of+an+rVSV+vaccine+against+Zika+virus+infection+in+macaca+nemestrina&rft.jtitle=Frontiers+in+virology+%28online%29&rft.au=Tisoncik-Go%2C+Jennifer&rft.au=Voss%2C+Kathleen+M.&rft.au=Lewis%2C+Thomas+B.&rft.au=Muruato%2C+Antonio+E.&rft.date=2023-01-01&rft.issn=2673-818X&rft.eissn=2673-818X&rft.volume=3&rft_id=info:doi/10.3389%2Ffviro.2023.1108420&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fviro_2023_1108420 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2673-818X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2673-818X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2673-818X&client=summon |